EagleClaw Capital Managment LLC Boosts Stock Position in Novo Nordisk A/S (NYSE:NVO)

EagleClaw Capital Managment LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 4.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 65,850 shares of the company’s stock after acquiring an additional 2,575 shares during the period. Novo Nordisk A/S makes up 1.3% of EagleClaw Capital Managment LLC’s investment portfolio, making the stock its 26th biggest holding. EagleClaw Capital Managment LLC’s holdings in Novo Nordisk A/S were worth $7,841,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. 1620 Investment Advisors Inc. purchased a new position in Novo Nordisk A/S in the 2nd quarter valued at approximately $25,000. Gilliland Jeter Wealth Management LLC increased its stake in Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after purchasing an additional 120 shares in the last quarter. Strategic Investment Solutions Inc. IL purchased a new position in Novo Nordisk A/S in the 2nd quarter valued at approximately $25,000. Halpern Financial Inc. increased its stake in Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares in the last quarter. Finally, Abound Wealth Management grew its holdings in Novo Nordisk A/S by 257.4% during the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after buying an additional 157 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

NVO stock traded up $0.76 during midday trading on Wednesday, reaching $103.39. The company had a trading volume of 471,032 shares, compared to its average volume of 4,464,422. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock has a 50 day moving average price of $117.40 and a 200 day moving average price of $129.27. The firm has a market capitalization of $463.97 billion, a PE ratio of 33.22, a P/E/G ratio of 1.31 and a beta of 0.42. Novo Nordisk A/S has a fifty-two week low of $94.73 and a fifty-two week high of $148.15.

Wall Street Analyst Weigh In

A number of brokerages have commented on NVO. BMO Capital Markets lowered their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.